Heparan sulfates from arteries and veins differ in their antithrombin-mediated anticoagulant activity

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 11, 2008, Pages 1987-1990

  De Mattos, D A ^a   Stelling, M P ^a   Tovar, A M F ^a   Mourão, Paulo A S ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; HEPARAN SULFATE; HEPARIN;

ANTICOAGULATION; CARBOHYDRATE ANALYSIS; CAVA VEIN; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; LETTER; MOLECULAR SIZE; PRIORITY JOURNAL; THORACIC AORTA;

ANTICOAGULANTS; ANTITHROMBINS; ARTERIES; HEPARITIN SULFATE; HUMANS; VEINS;

EID: 54149096721     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03145.x     Document Type: Letter

References (17)

1. Schoen FJ, Cotran RS. Blood vessels. In: Cotran RS, Kumar V, Collins T, eds. Robbins Pathological Basis of Disease. Philadelphia: WB Saunders, 1994: 467-516.
2. Hansson GK, Robertson AL, Söderberg-Nauclér C. Inflammation and atherosclerosis. Annu Rev Pathol Mech Dis 2006; 1: 297-329.
3. Corti R, Hutter R, Badimon JJ, Fuster V. Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis. J Thromb Thrombolysis 2004; 17: 35-44.
4. Thomas D, Roberts HR. Hypercoagulability in venous and arterial thrombosis. Ann Intern Med 1997; 126: 638-44.
5. Rosenberg RD, Aird WC. Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med 1999; 340: 1555-64.
6. de Agostini AI, Watkins SC, Slayter HS, Youssoufian H, Rosenberg RD. Localization of anticoagulantly active heparan sulfate proteoglycans in vascular endothelium: Antithrombin binding on cultured endothelial cells and perfused rat aorta. J Cell Biol 1990; 111: 1293-304.
7. Bombeli T, Mueller M, Haeberli A. Anticoagulant properties of vascular endothelium. Thromb Haemost 1997; 77: 408-23.
8. Mammen EF. Antithrombin: Its physiological importance and role in DIC. Semin Thromb Hemost 1998; 24: 19-25.
9. Tovar AM, de Mattos DA, Stelling MP, Sarcinelli-Luz BS, Nazareth RA, Mourao PAS. Dermatan sulfate is the predominant antithrombotic glycosaminoglycan in vessel walls: Implications for a possible physiological function of heparin cofactor. II. Biochim Biophys Acta 2005; 1740: 45-53.
10. Leta GC, Mourão PAS, Tovar AMF. Human venous and arterial glycosaminoglycans have similar affinity for plasma low-density lipoproteins. Biochim Biophys Acta 2002; 1586: 243-53.
11. Rosenberg RD, Shworak NW, Liu J, Schwartz JJ, Zhang L. Heparan sulfate proteoglycans of the cardiovascular system. J Clin Invest 1997; 99: 2062-70.
12. Cardoso LEM, Mourão PAS. Glycosaminoglycan fractions from human arteries presenting diverse susceptibilities to atherosclerosis have different binding affinities to plasma LDL. Arterioscler Thromb 1994; 14: 115-24.
13. Werneck CC, Cruz MS, Silva LCF, Villa-Verde DMS, Savino W, Mourão PAS. Is there a glycosaminoglycan-related heterogeneity of the thymic epithelium? J Cell Physiol 2000; 185: 68-79.
14. Streusand VJ, Björk I, Gettins PGW, Petitou M, Olson ST. Mechanism of acceleration of antithrombin-proteinase reactions by low affinity heparin. J Biol Chem 1995; 270: 9043-51.
15. HajMohammadi S, Enjyoji K, Princivalle M, Christi P, Lech M, Beeler D, Rayburn H, Schwartz JJ, Barzegar S, de Agostini AI, Post MJ, Rosenberg RD, Shworak NW. Normal levels of anticoagulant heparan sulfate are not essential for normal hemostasis. J Clin Invest 2003; 111: 989-99.
16. Dewerchin M, Hérault JP, Wallays G, Petitou M, Schaeffer P, Millet L, Weitz JI, Moons L, Collen D, Carmeliet P, Herbert JM. Life-threatening thrombosis in mice with targeted Arg48-to-Cys mutation of the heparin-binding domain of antithrombin. Circ Res 2003; 93: 1120-6.
17. Duncan MB, Chen J, Krise JP, Liu J. The biosynthesis of anticoagulant heparan sulfate by the heparan sulfate 3-O-sulfotransferase isoform. 5. Biochim Biophys Acta 2004; 1671: 34-43.